Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29764514 | 0.82 | MEN1 (0.86) | MEN1KMT2AGAAKDM4ELMNA | |
| SCHEMBL6061686 | 0.82 | MEN1 (0.86) | MEN1KMT2AGAAKDM4ELMNA | |
| SCHEMBL5722067 | 0.79 | MEN1 (0.61) | MEN1KMT2AGAAKDM4ELMNA | |
| SCHEMBL15020608 | 0.78 | MEN1 (0.60) | MEN1KMT2AGAAKDM4ELMNA | |
| SCHEMBL6061687 | 0.77 | MEN1 (0.78) | MEN1KMT2AGAAKDM4ELMNA | |
| SCHEMBL28694741 | 0.77 | MEN1 (0.73) | MEN1KMT2AGAAKDM4ELMNA | |
| Oxalic Acid SCHEMBL7908190 | 0.76 | C5AR1 (0.54) | C5AR1LMNATSHROPRM1 | |
| SCHEMBL29918604 | 0.75 | MEN1 (0.60) | MEN1KMT2AGAAKDM4ELMNA | |
| SCHEMBL9260456 | 0.75 | MEN1 (0.69) | MEN1KMT2AGAAKDM4ELMNA | |
| SCHEMBL9260459 | 0.75 | MEN1 (0.69) | MEN1KMT2AGAAKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | MEN1 3887/4885KMT2A 1221/4885C5AR1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.